Beta Bionics vs Rxsight
Rxsight is the larger business, with $134m of revenue in fiscal 2025 against $100m for Beta Bionics (1.3 times as much). Beta Bionics grew faster (53.9% against -3.9%). Rxsight kept more of each dollar of sales as profit: a net margin of -29.0% against -73.0%. Beta Bionics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Beta BionicsBBNX, 2025 | RxsightRXST, 2025 |
|---|---|---|
| Revenue | $100m | $134m |
| Revenue growth | 53.9% | -3.9% |
| Net income | −$73.2m | −$38.9m |
| Operating margin | -71.5% | -35.8% |
| Net margin | -73.0% | -29.0% |
| Return on equity | — | -14.0% |
| Free cash flow | −$56.2m | −$19.3m |
| Cash | $31.6m | $19.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 420 | 461 |
| Market value | $817m | $192m |
| Price vs our value range | — | — |
| Moat score | — | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 52 sales | 0 buys, 4 sales |